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Currently, the DNA damage response (DDR) pathway represents a key target for new cancer
drug development. Advanced biliary tract cancer (BTC) has a poor prognosis because of the
lack of efficacious treatment options. Although DNA repair pathway alterations have been
reported in many patients with BTC, little is known regarding the effects of DDR-targeted
agents against BTC.  
Materials and Methods
In this study, nine BTC cell lines were exposed to the WEE1 inhibitor (AZD1775). In vitro,
MTT assay, colony-forming assay, cell cycle analysis, phospho-histone H3 staining assay,
Transwell migration assay, and western blot were performed. Then, to enhance the anti-
tumor effect of AZD1775, the combination treatment of WEE1 inhibitor and ataxia telang-
iectasia mutated and Rad3 related (ATR) inhibitor (AZD6738) was conducted using MTT
assay and comet assay. Finally, HuCCT-1 and SNU2670 xenograft models were established
to confirm the anti-tumor effect of AZD1775 alone. Furthermore, the combination treatment
was also evaluated in SNU2670 xenograft models.     
Results
AZD1775 blocked the phosphorylation of CDC2 and CDC25C in all cell lines, but significantly
increased apoptosis and S phase arrest in sensitive cells. However, increased p-ATR and
phosphorylated ataxia telangiectasia mutated levels were observed in less sensitive cells.
In addition, in vitro and in vivo data illustrated that AZD1775 combined with AZD6738 
exerted more potent anti-tumor effects than either drug alone. Although WEE1 inhibition
has promising anti-tumor effects in some BTC cells, the addition of ATR inhibitors could 
enhance its efficacy.
Conclusion
Taken together, this study supports further clinical development of DDR-targeted strategies
as monotherapy or combination regimens for BTC.
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Introduction
Since the role of the DNA damage response (DDR) path-
way in cancer survival was discovered, targeting the DDR
pathway has been evaluated as a treatment strategy for 
diverse cancers [1]. As the core members of the DDR signal-
ing network, poly(ADP-ribose) polymerase (PARP), ataxia
telangiectasia mutated (ATM), ataxia telangiectasia mutated
and Rad3 related (ATR), and the nuclear kinase WEE1 con-
trol DNA damage repair via regulating cell cycle progres-
sion, apoptosis, chromatin remodeling, and oncogenic signa-
ling pathways [1]. In terms of the crucial actions of these
DDR-related mediators, PARP/ATM/ATR/WEE1 inhibitors
are under clinical development for solid tumors. Although
targeting the DDR pathway is an area of intense research
focus, little research has been devoted to its role in biliary
tract cancer (BTC), an aggressive cancer.
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To date, the first-line treatment for patients with advanced
BTC is a gemcitabine/cisplatin combination, of which clini-
cal outcome is limited [2,3]. Given the huge unmet medical
needs, potential targeted agents should be thoroughly devel-
oped in BTC. Previous studies reported that TP53 and reti-
noblastoma protein (RB) module alterations were found in
33.9% and 11.7% of patients with BTC, respectively [4]. One
of the major functions of TP53 and RB is control of the G1-S
cell cycle transition [5]. However, because of G1/S check-
point dysfunction, the cells were more dependent on G2/M
checkpoint proteins, such as WEE1, for survival [6,7]. In 
addition, alterations in DNA damage repair-related genes,
including breast cancer 1/2 (BRCA1/2), BRCA1 associated
protein-1, and histone-lysine N-methyltransferase 2D, were
also found in approximately 20% of patients with BTC [4].
These characteristics support BTC as a good model for the
development of DDR-targeted agents, especially WEE1 inhi-
bitors. 
The nuclear kinase WEE1 is an important cell cycle regu-
lator that inhibits cyclin-dependent kinase 1 activity, and it
participates in the homologous recombinant pathway to 
repair DNA damage [1,6]. Because of this role, preclinical
studies have tested WEE1 inhibition in DDR-deficient cancer
cells, which showed that WEE1 blockade could induce strong
anti-tumor effects through enhancing DNA damage, G2/M
arrest, and apoptosis [8,9]. However, WEE1 inhibition has
not yet been evaluated in BTC cells. 
In our work, the anti-tumor effects of AZD1775 [6], a 
potent WEE1 kinase inhibitor, in BTC were explored. In the
study, we aimed to elucidate the mechanism of sensitivity to
WEE1 inhibitor in BTC using in vitro and in vivo experiments. 
Materials and Methods
1. Human cell lines and reagents
Nine human BTC cell lines were utilized in this study.
SNU245, SNU308, SNU478, SNU869, and SNU1196 cells
were purchased from Korean Cell Line Bank (Seoul, Korea).
HuCCT-1 and TFK-1 cells were obtained from RIKEN BioRe-
source Center (Ibaraki, Japan). The patient-derived cell lines
SNU2670 and SNU2773 were successfully established as 
described previously [10]. All cells were cultured in RPMI-
1640 medium (Welgen Inc., Gyeongsan, Korea) containing
10% fetal bovine serum and 10 µg/mL gentamicin at 37°C
under 5% CO2. WEE1 (AZD1775), ATR (AZD6738), and
ATM (AZD0156) inhibitors were kindly provided by Astra-
Zeneca (Macclesfield, Cheshire, UK).
2. Cell viability assay
Cells were seeded in 96-well plates and incubated over-
night at 37°C. The cells were exposed to increasing concen-
trations of AZD1775 alone or in combination with AZD6738
(ATR inhibitor) or AZD0156 (ATM inhibitor) for 3 days.
Next, 50 µL of 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetra-
zolium bromide (MTT) solution (Sigma-Aldrich, St. Louis,
MO) were added to each well, and plates were incubated at
37°C for 4 hours. The medium was removed, and 150 µL of
dimethyl sulfoxide were added to each well. Cell viability
was measured at 540 nm using a VersaMax Microplate Rea-
der (Molecular Devices, Sunnyvale, CA). The experiments
were performed in triplicate. 
3. Colony-forming assay
Cells were seeded in 6-well plates and exposed to various
concentrations of AZD1775. After 10 days, the colonies were
stained with Coomassie blue for 2 hours and counted using
Gel Doc system software (Bio-Rad, Hercules, CA). Each 
experiment was repeated three times. 
4. Western blot analysis 
Cells were seeded in 60-mm dishes and treated with AZD-
1775, AZD6738, or both for 24 hours. The cells were har-
vested and lysed in RIPA buffer containing protease inhi-
bitors on ice for 30 minutes. The proteins were extracted, and
equal amounts of proteins were used for western blot analy-
ses. Primary antibodies against the following molecules were
purchased from Cell Signaling Technology (Beverley, MA):
WEE1 (#4936), p-WEE1-Ser642 (#4910), ATR (#2790), phos-
phorylated ATR-Ser428 (#2853), Chk1 (#2360), phosphory-
lated Chk1-Ser345 (#2341), PARP (#9532), caspase-7 (#9492),
phosphorylated AKT-Ser473 (#9271), AKT (#9272), phospho-
rylated CDC25C-Ser216 (#9528); CDC25C (#4688); phospho-
rylated CDC2 (#9111), CDC2 (#9112), and p21 (#2947). !-Actin
antibody was purchased from Sigma-Aldrich. Anti-ATM
(#ab78) and phosphorylated ATM-Ser1981 (#ab81292) anti-
bodies were obtained from Abcam Bioscience (Cambridge,
UK). Anti-"H2AX antibody (#05-636) was bought from Mil-
lipore (Billerica, MA). Secondary antibodies were acquired
from Thermo Fisher Scientific Inc. (Waltham, MA). 
5. Cell cycle analysis 
Cells were seeded in 60-mm dishes and treated with vari-
ous concentrations of AZD1775 for 24 hours. The cells were
harvested and fixed with 70% ethanol at !20°C. After 2 days,
7 µL of RNase A (20 mg/mL, Invitrogen, Carlsbad, CA) were
added to each well and incubated for 10 minutes at 37°C. The
946 CANCER  RESEARCH  AND  TREATMENT
Ah-Rong Nam, DDR-Targeting Strategy in Biliary Tract Cancer
cells were stained with 13 µL of propidium iodide (Sigma-
Aldrich) and analyzed using a FACSCalibur flow cytometer
(BD Biosciences, San Jose, CA). Each experiment was repea-
ted three times.
6. Phospho-histone H3 staining assay
Cells were seeded in 60-mm dishes and incubated with
AZD1775 for 24 hours. Then, cells were fixed with 70%
ethanol at least 4 hours at !20°C. After washing with staining
buffer (#420201, BioLegend, San Diego, CA), 20 µL of phos-
pho-histone H3 (p-HH3) antibody (#558217, BD Bioscience)
and 80 µL of staining buffer were added for 20 minutes at
room temperature. Cells were washed with staining buffer
once and incubated with 300 µL of staining buffer and 3.5 µL
of RNase A for 10 minutes at 37°C. Next, 13 µL of propidium
iodide were added, and cells were analyzed using a FAC-
SCalibur flow cytometer. Each experiment was repeated
three times.
7. Transwell migration assay
Migration assays were conducted using 6.5-mm Transwell
insert chambers with 8-µm-pore polycarbonate membranes
(#CLS3422, Sigma-Aldrich). Cells were seeded into the upper
chamber in 200 µL of medium containing 0.1% fetal bovine
serum (FBS), and 500 µL of medium containing 10% FBS
were added to the lower chamber. AZD1775 was added to
the upper chamber, and the plates were incubated at 37°C
for 24 hours. The non-migrated cells remaining on the upper
side of the membranes were removed with cotton swabs, and
the filters were fixed with 4% paraformaldehyde (#P2031,
Biosesang, Seongnam, Korea) for 20 minutes at room tem-
perature. The membranes were then incubated in 1% crystal
violet solution (#V5265, Sigma-Aldrich) for 10 minutes. The
cells were visualized using a microscope and photographed,
after which they were then dissolved by incubating the mem-
branes in 300 µL of 33% acetic acid (#1.00063.2511, Merck,
Darmstadt, Germany) for 10 minutes. The liquid was col-
lected, and the absorbance at 573 nm was measured using a
microplate reader. The experiment was repeated three times. 
8. Alkaline comet assay 
Cells were exposed to 1 µmol/L AZD1775, 1 µmol/L AZD-
6738, or both for 24 hours. Then, the cells were harvested,
and alkaline comet assay was performed as previously des-
cribed [11]. The tail moment and intensity were measured
using the Comet Assay IV program (Andor Technology,
Belfast, UK). Three independent experiments were analyzed
for each condition.
9. In vivo experiments
Animal experiments were performed at the Institute for
Experimental Animals, College of Medicine, Seoul National
University (Seoul, Korea) according to institutional guide-
lines, with prior approval from the Institutional Animal Care
and Use Committee. Four-week-old female athymic nude
mice were purchased from Orient Bio Inc. (Seongnam, Korea).
HuCCT-1 and SNU2670 xenograft model mice were estab-
lished via subcutaneous inoculation of 1"107 cells in 100 µL
of phosphate buffered saline. When the tumor volume rea-
ched 200 mm3, the mice were randomly divided into two or
four groups of five mice. AZD1775 (25, 60, or 90 mg/kg) and
AZD6738 (25 mg/kg) were administered orally once a day
for 3 weeks (5 days on/2 days off), and the control group was
treated with vehicle (2-hydroxypropyl-!-cyclodextrin solu-
tion, Sigma-Aldrich) via oral gavage. Body weights and
tumor sizes were measured every other day. The tumor vol-
ume was calculated using the following formula: tumor vol-
ume=[(width)2"height]/2.
10. Immunohistochemistry 
Sections of paraffin-embedded xenograft tumor tissues
were deparaffinized and dehydrated. Immunohistochemical
(IHC) detection of p-ATR (#2853, Cell Signaling) expression
and proliferating cells was conducted using an anti-Ki-67 
antibody (GeneTex Inc., Irvine, CA) at a dilution of 1:100.
Terminal deoxynucleotidyl transferase-mediated dUTP nick
end labeling (TUNEL) assays were conducted for the immu-
nohistochemical detection of apoptosis using an ApopTag In
Situ Apoptosis Detection Kit (EMD Millipore) according to
the manufacturer’s protocol. 
11. Statistical analysis
Statistical analyses were conducted using SigmaPlot ver.
10.0 (Systat Software Inc., San Jose, CA). Experimental data
are presented as the mean±standard error. All statistical tests
were two-sided. Differences were considered statistically sig-
nificant at p < 0.05. The half-maximal inhibitory concentra-
tion (IC50) of agents was also analyzed using SigmaPlot
software. Combined drug effects were analyzed by calculat-
ing the combination index (CI) using CalcuSyn software
(Biosoft, Cambridge, UK). CIs of < 1, 1, and > 1 indicate syn-
ergistic, additive, and antagonistic effects, respectively. 
12. Ethical statement
Animal experiments were performed at the Biomedical
Center for Animal Resource Development of Seoul National
University (Seoul, Korea) according to institutional guide-
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lines, and prior approval of the study protocol was obtained
from the Institutional Animal Care and Use Committee.
Results 
1. The anti-proliferative effects of WEE1 inhibition in BTC
cells
To evaluate whether WEE1 inhibition has anti-proliferative
effects in BTC cells, the MTT assay was performed after treat-
ing cells with various concentrations of AZD1775 for 72
hours. Among the nine cell lines, viability was more strongly
suppressed by AZD1775 in SNU308, SNU478, SNU869,
Cancer Res Treat. 2020;52(3):945-956
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Fig. 1.  Anti-proliferative effect of AZD1775 in biliary tract cancer (BTC) cells. (A) The anti-proliferative effects of AZD1775
in nine BTC cell lines were evaluated using the 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assay
after 72 hours. (B) The half-maximal inhibitory concentration (IC50) of AZD1775 in the MTT assay was calculated. (C) Western
blot analyses of the effects of AZD1775 on signaling pathways in four BTC cell lines. Cells were treated with increasing con-
centrations of AZD1775 (0, 0.1, 0.5, and 1 µM) for 24 hours.
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SNU1196, HuCCT-1, and TFK-1 cells than in SNU245, SNU-
2670, and SNU2773 cells (Fig. 1A and B). According to the
sensitivity, we selected four cell lines for the subsequent 
experiments. SNU308 (KRAS/TP53 mutation) and HuCCT-
1 (KRAS/TP53/RAD51/BRCA2 mutation) are relatively sen-
sitive cells, and SNU2773 (HER2 positive) and SNU2670
(BRAF mutation/ HER2 positive) are relatively insensitive
cells. 
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Fig. 2.  The effect of AZD1775 alone in biliary tract cancer (BTC) cells. (A) Cell cycle analyses were performed by flow cyto-
metry after treatment with increasing concentrations of AZD1775 (0, 0.1, 0.5, and 1 µM) for 24 hours. The data represent
three independent experiments. *p < 0.05. (B) The phospho-histone H3 (p-HH3)–positive population in S phase was analyzed
using flow cytometry after treatment with AZD1775 (0 and 1 µM) for 24 hours. The data represent three independent exper-
iments. *p < 0.05. (C) Western blot analyses of the effects of AZD1775 on cell cycle pathways in four BTC cell lines. Cells
were treated with increasing concentrations of AZD1775 (0, 0.1, 0.5, and 1 µM) for 24 hours. PARP, poly(ADP-ribose) poly-
merase. (Continued to the next page)
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The colony-forming assay was conducted 10 days after
treatment with AZD1775. As shown in S1 Fig., AZD1775 dra-
matically reduced colony formation in all four cell lines, 
especially SNU308 cells (S1A and S1B Fig.). To confirm this
observation, we detected the related DNA damage signals at
24 hours after treatment (Fig. 1C). Interestingly, AZD1775 as
a WEE1 kinase inhibitor downregulated WEE1 total levels in
all four cell lines. According to previous research on AZD-
1775, probably because reduced levels of transcription factors
or PLK1 prevented WEE1 expression [12,13]. In addition, 
increased p-Chk1 and !-H2AX levels and decreased p-CDC2
level was observed in all four cells. However, p-CDC25C was
reduced in all four cell lines. In general, CDC25C phospho-
rylation at Ser216 is accompanied by an increase in p-Chk1/
p-Chk2, but we have not observed a canonical signaling 
relationship between them in BTC cell lines.    
2. WEE1 inhibition induces S phase arrest, apoptosis and
suppresses migration in sensitive cells
To analyze AZD1775-mediated cell cycle regulation, cells
were incubated with AZD1775 for 24 hours and then exam-
ined using flow cytometry. WEE1 inhibition led to significant
S phase arrest in SNU308, HuCCT-1, and SNU2773 cells but
not in SNU2670 cells (Fig. 2A). But AZD1775 induced S phase
arrest in SNU2670 cells within 48 hours, and the sub-G1 pop-
ulation still no changed (data not shown, p < 0.01). The num-
ber of p-HH3–positive cells in S phase was remarkably
increased for SNU308, HuCCT-1, and SNU2773 cells (Fig. 2B).
We also observed increased sub-G1 population, which rep-
resents apoptosis, in SNU308 and HuCCT-1 cells (Fig. 2A).
In addition, we detected related signals under the same con-
ditions. Compared with the findings in SNU2773 and SNU-
2670 cells, cleaved PARP and caspase-7 levels, as well as p21
levels, were strongly increased in SNU308 and HuCCT-1
cells (Fig. 2C). 
Next, the Transwell migration assay was performed 
because the effects of DDR-targeted agents on cell migration
have rarely been reported. Interestingly, WEE1 inhibition 
resulted in significant blockade of cell migration within 24
hours in both SNU308 and HuCCT-1 cells, but not in SNU-
2773 and SNU2670 cells (Fig. 2D and E).  
3. ATM/ATR activation correlates with sensitivity of BTC
cells to WEE1 inhibition
Having examined the effects of AZD1775 in BTC cells, we
sought to explain the difference in sensitivity of the cells to
WEE1 inhibition. We measured ATM and ATR levels after
treatment with AZD1775 in the four cell lines. Interestingly,
p-ATM and p-ATR expression was concentration-depen-
dently downregulated in SNU308 and HuCCT-1 cells 
(Fig. 3A). On the contrary, both p-ATM and p-ATR levels
were increased in SNU2773 and SNU2670 cells after treat-
ment with AZD1775 (Fig. 3A). In DNA damage repair path-
ways, the ATM/ATR could be activated by many partners
[14,15]. WEE1 inhibition might reduce positive controller
such as TIP60, ETAA1, and TopBP1, or enhance negative
controller like histone linker 1.2. These results provided us
the rationale to assess combination treatment with WEE1 and
ATR (AZD6738)/ATM (AZD0156) inhibitors in BTC cells.
Next, to evaluate whether the combination regimens were


































Fig. 2.  (Continued from the previous page) (D, E) Transwell migration assays were conducted with or without AZD1775 treat-
ment (1 µM). The image was captured at 24 hours after treatment. The percentage of migratory cells was analyzed after
images were captured. Experiments were repeated three times. *p < 0.05. 
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synergistic, we conducted MTT assays for 72 hours. As
shown in Fig. 3B, strong synergistic effects were observed in
SNU2773 and SNU2670 cells for combined treatment with
AZD1775/AZD6738 or AZD1775/AZD0156. However, AZD-
1775/AZD6738 was slightly synergistic in SNU308 and
HuCCT-1 cells. 
To confirm the effects of the combination treatments on
DNA damage, a comet assay was performed. The tail inten-
sity and moment data revealed that both AZD1775/AZD-
6738 and AZD1775/AZD0156 synergistically induced DNA
damage in all four cell lines (Fig. 3C and D, S2 Fig.). In line
with the anti-proliferative assay, AZD1775 mono-treatment
significantly induced DNA damage in sensitive cells not in
less sensitive cells. We speculated that DNA damage might
be repaired through ATM or ATR activation in SNU2773 and
SNU2670 cells. Given that AZD6738 has more potent anti-
tumor effect in clinical trials compared to AZD0156 [15], we
detected related signals under the same conditions using the
AZD1775/AZD6738 combination. AZD1775-mediated p-
ATR upregulation was reduced by co-treatment with AZD-
6738. We also found that p-Chk1 was increased by AZD1775
in all four cell lines, but AZD6738 strongly blocked p-Chk1
expression. Co-treatment strongly downregulated p-CDC2 
expression and increased !-H2AX accumulation in all cell
lines. Cleaved caspase-7 expression was more increased by
combined treatment in less sensitive cells (Fig. 3E). We also
conducted Transwell migration assay under the combination
treatment. Although combination treatment did not show a
synergism, the combination treatment has strong ability to
suppress migration in SNU2773 and SNU2670 cell lines (data
not shown, p < 0.05). 
4. Co-targeting ATR and WEE1 exhibited synergistic anti-
tumor growth effects in xenograft models
After evaluating the combination regimens in vitro, we 
established two xenograft models using HuCCT-1 and SNU-
2670 cell lines to confirm our findings in vivo. AZD1775
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Fig. 3.  Combination effects of WEE1 and ataxia telangiectasia mutated and Rad3 related (ATR) inhibitors in biliary tract cancer.
(A) Western blotting was performed after treated with various concentrations of AZD1775 (0, 0.1, 0.5, and 1 µM) for 24 hours.
ATM, ataxia telangiectasia mutated. (B) The combination indices (CIs) in the 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetra-
zolium bromide assay after combination treatment with AZD1775 (0, 0.001, 0.01, 0.1, 1, and 10 µM) and AZD0156 (0, 0.001,
0.01, 0.1, 1, and 10 µM)/AZD6738 (0, 0.001, 0.01, 0.1, 1, and 10 µM) for 72 hours. CI value was analyzed using CalcuSyn soft-
ware. CI > 1, 1, and < 1 indicate antagonistic, additive, and synergistic effects, respectively. (Continued to the next page)
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Fig. 3.  (Continued from the previous page) (C, D) Comet assays were conducted after treatment with AZD1775 (1 µM), AZD6738
(1 µM), or both for 24 hours. The tail intensity and moment were analyzed using the Comet Assay IV program. Experiments
were repeated three times. *p < 0.05, **p < 0.01. (E) Cells were incubated with AZD1775 (1 µM), AZD6738 (1 µM), or both for
24 hours, and then western blotting was performed. 
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monotherapy suppressed tumor growth in HuCCT-1 xeno-
graft mice at a low dose (25 mg/kg); however, the therapy
did not inhibit tumor growth in SNU2670 xenograft mice
(Fig. 4A). At a high dose (90 mg/kg) in relatively sensitive
HuCCT-1 xenograft mice, AZD1775 nearly blocked tumor
growth. In relatively insensitive SNU2670 xenograft mice,
AZD1775 also inhibited tumor growth. 
Based on this observation, we conducted combination
treatment using AZD1775 (60 mg/kg) and AZD6738 (25 mg/
kg) in SNU2670 xenograft mice. Notably, neither AZD1775










































































































Fig. 4.  Anti-tumor effects of AZD1775 alone and in combination with AZD6738 in xenograft mouse models. (A) HuCCT-1
and SNU2670 xenograft mice were administrated vehicle or AZD1775 (25 or 90 mg/kg) for 3 weeks (5 days on/2 days off).
Each group contained five mice. *p < 0.05. (B) SNU2670 xenograft mice were treated with vehicle, AZD1775 (60 mg/kg),
AZD6738 (25 mg/kg), or both AZD1775 and AZD6738 for 3 weeks (5 days on/2 days off). Each group contained five mice.
TE, end of treatment. *p < 0.05. (Continued to the next page)
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nor AZD6738 monotherapy efficiently suppressed tumor
growth, but the combination regimen significantly inhibited
tumor growth (Fig. 4B). During the experiment, we did not
observe body weight loss in any animals (S3 Fig.).
At the end of the experiment, the tumors of the mice were
isolated, and p-ATR, Ki-67, and TUNEL expression was eval-
uated via IHC (Fig. 4C). As expressed, decreased Ki-67 and
increased TUNEL levels were observed following AZD1775
(90 mg/kg) monotherapy in HuCCT-1 and SNU2670 xeno-
graft mice (Fig. 4C). Downregulation of Ki-67 and upregula-
tion of TUNEL expression were maintained in combination
treatment groups (Fig. 4C). In addition, p-ATR upregulation
induced by AZD1775 was efficiently reduced by the combi-
nation regimen. 
To confirm these observations, we detected cell prolifera-
tion and DNA damage markers such as p-AKT, p-ATR,
WEE1, p-WEE1, and !-H2AX. Consistent with the tumor
growth curve and IHC results, AD1775 (90 mg/kg) alone
dramatically blocked p-WEE1, WEE1, and p-AKT expression
and upregulated !-H2AX expression in both HuCCT-1 and
SNU2670 xenograft mice (Fig. 4D). In the SNU2670 xenograft
model, co-treatment with AZD1775 and AZD6738 dramati-
cally upregulated !-H2AX and downregulated p-AKT 
expression (Fig. 4D). 
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Fig. 4.  (Continued from the previous page) (C) H&E staining (!400) and immunohistochemical analysis (!400) of p-ataxia
telangiectasia mutated and Rad3 related (ATR), Ki-67, and terminal deoxynucleotidyl transferase-mediated dUTP nick end
labeling (TUNEL) expression were performed using isolated HuCCT-1 and SNU2670 tumors. (D) Western blot analysis of
various proteins in isolated tumors. 
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Discussion 
Our study highlighted that ATM or ATR activation redu-
ced the efficacy of WEE1 inhibition in BTC cells, and dual 
inhibition of ATR and WEE1 displayed potent anti-tumor 
effects both in vitro and in vivo. 
In the current study, we focused on the resistance mecha-
nism of AZD1775 and demonstrated that dual blockade of
WEE1 and ATM or ATR has potent anti-tumor effects in
BTC. AZD1775 reduced p-ATM and p-ATR levels in rela-
tively sensitive cells, but in less sensitive cells, both p-ATM
and p-ATR levels were elevated by AZD1775 (Fig. 3A). 
Another study described that WEE1 inhibition dramatically
downregulated ATM expression in AZD1775-sensitive gas-
tric cancer cells [16]. The other study reported that breast can-
cer cells were sensitive to WEE1 inhibition, and the IC50 was
less than 1 µM in most cell lines [17]. However, they found
that p-ATM and p-ATR expression was significantly upreg-
ulated by AZD1775 in a concentration- and time-dependent
manner. Inconsistent with the other tumor types, WEE1 inhi-
bition impairs p-ATM or p-ATR expression in BTC sensitive
cells.
WEE1 inhibition could suppress cell migration in sensitive
BTC cells (Fig. 2D). Although the potential anti-tumor effects
of DDR-targeted agents have been evaluated in different can-
cer types, their effects on migration have not been well stud-
ied. Recently, in line with our data, other study reported that
AZD1775 has an anti-migration/invasion effect in gastric
cancer; however, the mechanism was not elucidated [18].
ATM is also associated with cell migration via interleukin-8
regulation [19]. As shown in Fig. 2D, AZD1775 did not 
impair the migration of less sensitive cells. It could be spec-
ulated that activated ATM or ATR facilitated cell migration
even in the presence of WEE1 inhibition. Our result suggests
that DDR core members have a critical role in cell migration. 
Given the encouraging effects of DDR-targeted agents
against multiple cancer types [1], the anti-tumor effect of
these compounds urgently need to be evaluated in BTC. 
In triple-negative breast cancer, WEE1 inhibition overcame
cisplatin resistance by disrupting DNA replication and G2/
M cell cycle checkpoint regulation [20]. A clinical trial also
revealed that BTC patients harboring DDR-related gene 
mutations responded better to cisplatin therapy than those
with wild-type cancer [21]. Because cytotoxic chemotherapy
is the standard treatment for advanced BTC, targeting DDR
signaling pathways is extremely important for improving the
efficacy of chemotherapeutic agents against BTC. Recently,
we demonstrated that ATMlow/p53low BTC cells were sensi-
tive to ATR inhibitors, and combination treatment with 
cytotoxic chemotherapeutic agents synergistically induced
DNA damage [10]. These data illustrated that BTC is a good
candidate for implementing DDR-targeted agents. 
Accumulating evidence has revealed that DDR signaling
pathways modulate the tumor microenvironment via immune
response networks in many cancer types [22,23]. WEE1 inhi-
bition enhances the efficacy of programmed cell death-1–tar-
geted treatment efficacy by amplifying cytotoxic T-lympho-
cyte killing ability [22]. Some studies also discovered that
ATR inhibition-mediated downregulation of programmed
cell death ligand-1 expression facilitated CD8+ T cell toxicity
[23]. Based on these roles in immune modulation, we specu-
lated that the combination of WEE1 and ATR inhibition
might more potently activate T cell-dependent cytotoxicity
in BTC. This should be further studied. 
To date, co-targeting of WEE1 and ATR has rarely been 
investigated, although one study reported that this combi-
nation had a potent anti-tumor effect in triple-negative breast
cancer [17]. The researchers demonstrated that Rad51 inacti-
vation and !-H2AX accumulation were more significantly
observed after combination treatment. Notably, ATR inhi-
bitor as single agents has been evaluated in HER2-positive
breast cancer [24]. The investigators found that AZD6738 
reduced several DNA repair proteins and p-AKT levels in
sensitive cells but not in insensitive cells. The earlier studies
have been demonstrated that AKT involves in DNA damage
repair especially through non-homologous end joining path-
way [25]. In our study, p-AKT level was blocked by AZD-
1775 or AZD6738 in both HuCCT-1 and HER2-positive SNU-
2670 xenograft models (Fig. 4D). Although we have not fur-
ther elucidated how AZD1775 or AZD6738 mediate p-AKT
level, it is meaningful for additional investigation using this
combination strategy in BTC.      
Taken together, DDR-targeted treatment using WEE1 and
ATR inhibitors exerted potent anti-tumor effects in both in
vitro and xenograft models of BTC. These findings support
further clinical development of the DDR-targeted strategy in
patients with BTC. Our data indicated that DDR-targeted
combination treatment could represent a potential treatment
strategy for patients with BTC.
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